Tenaya (TNYA) CEO Ali Faraz Receives Equity Awards

What Happened
Ali Faraz, CEO of Tenaya Therapeutics (TNYA), received equity awards on September 10, 2026: 122,000 restricted stock units (RSUs) and a derivative award covering 732,500 shares. Both grants are reported at $0.00 per share (no cash paid at grant). Aggregate awards total 854,500 shares as reported in the Form 4.

Key Details

• Transaction date: 2026-09-10; Form 4 filed 2026-09-11 (appears timely).
• Grants: 122,000 RSUs (F1/F2) and 732,500 derivative award (reported as A/derivative). Grant price shown as $0.00 for both.
• Vesting: RSUs vest as to 1/8th of the award on Feb 15, 2027, then 1/8th every six months thereafter until fully vested (F2). The derivative award follows an option-style vesting of 1/48th monthly starting one month after the grant (F4).
• Footnote F3: filing notes 384,069 shares will be issued upon vesting of restricted stock units (as reported).
• Shares owned after transaction: not specified in the provided excerpt.
• No 10b5-1 plan, tax withholding, or sales noted in the supplied details.

Context
These transactions are grants (compensation-driven awards), not open-market purchases or sales. RSUs and option-style derivative awards typically vest over time and do not represent immediate stock purchases or liquidity events. Such grants are common for executive pay and should be interpreted as compensation rather than a direct market vote by the insider.